Short Interest in Enzo Biochem, Inc. (NYSE:ENZ) Declines By 10.0%

Enzo Biochem, Inc. (NYSE:ENZ) was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 531,800 shares, a drop of 10.0% from the July 15th total of 591,200 shares. Based on an average trading volume of 119,600 shares, the short-interest ratio is currently 4.4 days. Approximately 1.5% of the shares of the company are sold short.

Institutional Trading of Enzo Biochem

Several institutional investors and hedge funds have recently modified their holdings of ENZ. XTX Topco Ltd grew its stake in Enzo Biochem by 94.5% during the second quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 13,735 shares in the last quarter. Wittenberg Investment Management Inc. purchased a new position in Enzo Biochem during the fourth quarter valued at $95,000. Finally, Renaissance Technologies LLC grew its stake in Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock valued at $2,725,000 after acquiring an additional 64,417 shares in the last quarter. 36.90% of the stock is currently owned by institutional investors.

Enzo Biochem Stock Up 1.8 %

ENZ traded up $0.02 during trading on Friday, hitting $1.13. The company’s stock had a trading volume of 86,314 shares, compared to its average volume of 107,824. Enzo Biochem has a one year low of $0.99 and a one year high of $1.68. The business’s 50 day simple moving average is $1.11 and its 200-day simple moving average is $1.17.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Thursday, June 13th. The medical research company reported ($0.03) EPS for the quarter. The firm had revenue of $8.02 million for the quarter. Enzo Biochem had a net margin of 134.17% and a negative return on equity of 21.50%.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.